NLM Digital Collections

Search

Search Constraints

Start Over You searched for: Languages English Remove constraint Languages: English Genre Technical Report Remove constraint Genre: Technical Report Copyright Public domain Remove constraint Copyright: Public domain

Search Results

4. 30-Day notices, 135-day premarket approval (PMA) supplements and 75-day humanitarian device exemption (HDE) supplements for manufacturing method or process changes: guidance for industry and Food and Drug Administration staff

7. ACF cannot ensure that all child victims of abuse and neglect have court representation

9. ACOs' strategies for transitioning to value-based care: lessons from the Medicare shared savings program

13. Abuse and neglect: CMS should strengthen reporting requirements to better protect individuals receiving hospice care : report to the Honorable Charles E. Grassley, United States Senate

15. Access and use of electronic health information by individuals with cancer: 2017-2018

17. Access to preventive services without cost-sharing: evidence from the Affordable Care Act

18. The Accreditation Scheme for Conformity Assessment (ASCA) Pilot Program: guidance for industry, accreditation bodies, testing laboratories, and Food and Drug Administration staff

20. Acne vulgaris: establishing effectiveness of drugs intended for treatment

23. Adaptive designs for clinical trials of drugs and biologics

24. Addressing social determinants of health: examples of successful evidence-based strategies and current federal efforts

26. Administrative procedures for CLIA categorization: guidance for industry and Food and Drug Administration staff

27. Adolescent and young adult substance use: federal grants for prevention, treatment, and recovery services and for research : report to Congressional committees

28. Advance care planning among Medicare fee-for-service beneficiaries and practitioners: final report

30. Advancement of emerging technology applications for pharmaceutical innovation and modernization

32. Advancing primary prevention in human services. Key considerations for administrators and practitioners

33. Advancing primary prevention in human services. Key considerations for policy designers and funding partners

34. Advancing primary prevention in human services. Opportunities for people with lived experience

35. Advancing primary prevention in human services: convening findings

37. Adverse events in long-term-care hospitals: national incidence among Medicare beneficiaries

40. Affordable Care Act: IRS should mitigate limitations of data to be used for the age and gender adjustment for the tax on high-cost health plans : report to Congressional committees

41. The aging services network: accomplishments and challenges in serving a growing elderly population

42. Air ambulance: data collection and transparency needed to enhance DOT oversight : report to the Committee on Transportation and Infrastructure, House of Representatives

44. Air travel and communicable diseases: status of research efforts and action still needed to develop federal preparedness plan : testimony before the Subcommittee on Space and Aeronautics, Committee on Science, Space, and Technology, House of Representatives

47. Allergic rhinitis: developing drug products for treatment

49. Alternative procedures for the manufacture of cold-stored platelets intended for the treatment of active bleeding when conventional platelets are not available or their use is not practical: guidance for industry

50. Amyotrophic lateral sclerosis: developing drugs for treatment

51. Analysis of 2017 premium changes and insurer participation in the Affordable Care Act's health insurance marketplaces

52. An analysis of private-sector prices for hospital admissions

55. Animal use in research: NIH should strengthen oversight of projects it funds at foreign facilities : report to congressional requesters

59. Anthrax: developing drugs for prophylaxis of inhalational anthrax

60. Antibacterial therapies for patients with an unmet medical need for the treatment of serious bacterial diseases

61. Antibiotic resistance: Federal agencies have taken steps to combat the threat, but additional actions needed : testimony before the Subcommittee on Oversight and Investigations, Committee on Energy and Commerce, House of Representatives

63. Antibiotic resistance: more information needed to oversee use of medically important drugs in food animals : report to Congressional requesters

64. Antibiotics: FDA has encouraged development, but needs to clarify the role of draft guidance and develop qualified infectious disease product guidance : report to Congressional requesters

66. Antipsychotic medication prescribing in long-term care facilities increased in the early months of the COVID-19 pandemic

67. Appeal options available to mammography facilities concerning adverse accreditation decisions, suspension/revocation of certificates, or patient and physician notification orders: guidance for mammography facilities and Food and Drug Administration staff

72. Appropriate use of voluntary consensus standards in premarket submissions for medical devices: guidance for industry and Food and Drug Administration staff

74. Arthroscopy pump tubing sets intended for multiple patient use - Premarket Notification (510(k)) submissions: guidance for industry and Food and Drug Administration staff

75. Artificial intelligence in health care: benefits and challenges of machine learning technologies for medical diagnostics : report to congressional requesters

76. As funding for BPA research increased, NIEHS followed its peer review process while also exercising its discretion

77. Assessing COVID-19-related symptoms in outpatient adult and adolescent subjects in clinical trials of drugs and biological products for COVID-19 prevention or treatment

81. Assessing user fees under the Prescription Drug User Fee Amendments of 2017

82. Assessing user fees under the biosimilar user fee amendments of 2017

84. Associations between county-level vaccination rates and COVID-19 outcomes among Medicare beneficiaries

85. Associations between county-level vaccination rates and COVID-19 outcomes among Medicare beneficiaries

87. BCG-unresponsive nonmuscle invasive bladder cancer: developing drugs and biologics for treatment

89. Bacterial risk control strategies for blood collection establishments and transfusion services to enhance the safety and availability of platelets for transfusion

91. Basic safety and essential performance of medical electrical equipment, medical electrical systems, and laboratory medical equipment: standards specific information for the Accreditation Scheme for Conformity Assessment (ASCA) Pilot Program : guidance for industry, accreditation bodies, testing laboratories, and Food and Drug Administration staff

92. Behavioral health and COVID-19: higher-risk populations and related federal relief funding : report to congressional committees

93. Behavioral health in rural America: challenges and opportunities

94. Behavioral health: Available workforce information and federal actions to help recruit and retain providers : report to congressional requesters

95. Best practices for communication between IND sponsors and FDA during drug development: guidance for industry and review staff : good review practice

98. Billions in estimated Medicare Advantage payments from chart reviews raise concerns

99. Billions in estimated Medicare Advantage payments from diagnoses reported only on health risk assessments raise concerns

100. Bioanalytical method validation